STOCK TITAN

VirnetX signs stock offering deal for up to $19.1M

Sales may occur on The Nasdaq Capital Market or other existing markets; privately negotiated transactions require VHC’s prior written consent.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

VirnetX Holding Corporation (VHC) entered into an at-the-market sales agreement under which it may sell, from time to time, an aggregate of up to $19,135,717 of common stock under its shelf registration statement. The company is not obligated to sell shares. Titan Partners Securities LLC will act as sales agent and use commercially reasonable efforts to sell shares on the company’s behalf, subject to the agreement.

Sales may be made on The Nasdaq Capital Market or another existing trading market, or to or through a market maker; privately negotiated sales require the company’s prior written consent. VHC agreed to pay the agent a 3.0% commission on the gross sales price of shares sold. The company intends to use net proceeds, if any, for product development, marketing and general corporate purposes, which may include working capital, capital expenditures and other corporate expenses.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
ATM program amount $19,135,717 Aggregate amount of common stock shares VHC may sell under the agreement
Sales agent commission 3.0% of gross sales price Commission on shares sold under the Sales Agreement
Common stock par value $0.0001 per share Par value of VHC common stock
at the market offering financial
"launch of an “at the market” offering program"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
net proceeds financial
"use the net proceeds from the sale of the Shares"
The amount of money a company actually keeps from a sale or fundraising after paying all direct costs and fees, similar to take-home pay after taxes and deductions. Investors care because net proceeds determine how much cash is available for things that affect value—paying debt, funding projects, buying assets, or returning money to shareholders—so it influences future growth potential and financial health.
prospectus supplement regulatory
"filed a prospectus supplement, dated October 1, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 415 regulatory
"an “at the market” offering as defined in Rule 415"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much common stock may VHC sell under its ATM program?

VHC may sell an aggregate of up to $19,135,717 of common stock under the agreement. The company may sell shares from time to time and is not obligated to sell any.

What commission does VHC pay its ATM sales agent?

VHC agreed to pay Titan Partners Securities LLC a 3.0% commission on the gross sales price of shares sold under the agreement.

How may VHC shares be sold under the ATM agreement?

Shares may be sold on The Nasdaq Capital Market or another existing trading market, or to or through a market maker. Privately negotiated sales require VHC’s prior written consent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549



FORM 8-K



CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
October 1, 2026



VirnetX Holding Corporation
(Exact name of registrant as specified in its charter)



Delaware
001-33852
77-0390628
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

308 Dorla Court, Suite 206
Zephyr Cove, Nevada 89448
(Address of principal executive offices, including zip code)

(775) 548-1785
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001
VHC
NASDAQ



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



ITEM 1.01.
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On October 1, 2026, in connection with the launch of an “at the market” offering program, VirnetX Holding Corporation (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with Titan Partners Securities LLC, as sales agent, (the “Agent”) pursuant to which the Company may sell, from time to time, an aggregate of up to $19,135,717 of shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”).

The Shares may be issued and sold from time to time through the Agent pursuant to the Company’s shelf Registration Statement on Form S-3 (File No. 333-295960). The Company has filed a prospectus supplement, dated October 1, 2026, pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the offer and sale of the Shares pursuant to the Sales Agreement. The Company intends to use the net proceeds from the sale of the Shares, if any, for product development, marketing and general corporate purposes, which may include working capital, capital expenditures and other corporate expenses.

The Company may, from time to time and subject to the terms of the Sales Agreement, sell the Shares thereunder, but is not obligated to sell any such Shares. Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts to sell, on the Company’s behalf, the Shares offered by the Company under the Sales Agreement, unless earlier terminated pursuant to the terms of the Sales Agreement. The Agent may sell such Shares by any methods deemed to be an “at the market” offering as defined in Rule 415 promulgated under the Securities Act, including without limitation sales made directly on The Nasdaq Capital Market or any other existing trading market for the Common Stock or to or through a market maker. With the Company’s prior written consent, the Agent may also sell Shares in privately negotiated transactions.

The Company has agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Shares sold pursuant to the Sales Agreement. The Sales Agreement contains customary representations, warranties and agreements of the Company and the Agent, indemnification rights and obligations of the parties and termination provisions.

The foregoing summary of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 hereto and incorporated herein by reference. The provisions of the Sales Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the Sales Agreement and are not intended as a document for investors and the public to obtain factual information about the Company’s current state of affairs. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the Securities and Exchange Commission (the “SEC”).

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Sales Agreement, nor shall there be any sale of such Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The legal opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation relating to the Shares being offered pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Forward-Looking Statements

Certain information in this Current Report on Form 8-K may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, statements regarding the Company’s sale of Shares under the Sales Agreement. These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements, including due to changes in economic and financial conditions, such as volatility in interest and exchange rates and in the capital or credit markets, and due to other factors discussed in the section titled “Risk Factors” in our Annual Report and Quarterly Reports and other documents filed with the SEC from time to time. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements.


ITEM 9.01.
FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

     
Incorporated by Reference Herein
 
Exhibit No.
 
Description
Form
Exhibit No.
Filing Date
File No.
Filed Herewith
1.1
 
At the Market Offering Agreement, dated as of October 1, 2026, by and between the Company and Titan Partners Securities LLC.
       
X
5.1
 
Opinion of Wilson Sonsini Goodrich & Rosati, P.C.
       
X
23.1
 
Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).
       
X
104
 
Cover Page Interactive Data File, formatted in inline XBRL.
         


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
VirnetX Holding Corporation
     
 
By:
/s/ Kendall Larsen
   
Kendall Larsen
   
Chief Executive Officer

Dated: October 1, 2026



Filing Exhibits & Attachments

5 documents

Keep reading